JLK, a Kosdaq-listed medical AI company, said Wednesday that it had been granted a U.S. patent for its device and method for providing brain lesion information.

The patent is a technology patent for a method that can accurately learn and analyze brain lesion areas in three-dimensional magnetic resonance angiography (MRA) images, providing a method for reducing the risk of stroke and monitoring through AI that can detect abnormal lesions in cerebrovascular areas.

To establish a technological barrier for entering the global market, JLK has successfully obtained various original technology patents for analyzing stroke and finding the cause of its occurrence in major developed markets such as the U.S., Europe, Japan, and China.

The diagnostic and therapeutic process for treating stroke patients, in particular, is complex and involves many considerations, as it relies on a combination of imaging and clinical information, including CT, CTA, CTP, MRI, and MRA.

JLK has built a full-cycle solution that analyzes and synthesizes various images, and the patent registration of the global original technology is expected to be a strong foundation for JKL to enter the U.S.

"Entering the U.S. market is an inevitable challenge and task to achieve our future vision and sales goals according to our roadmap for stroke paradigm shift," said Kim Dong-min, CEO of JLK. "We will enhance our global presence with a market strategy to expand sales in the U.S. and Japanese markets based on our differentiation of full-cycle stroke analysis."

Meanwhile, JLK announced on Jan.9 that it aims to achieve annual sales of 600 billion won ($456.5 million) by 2028 by boosting its AI services within the U.S. market.